(This article is authored by Alar)

In the shocking piece of news, Director General of the World Health Organisation, Tedros Adhanom Ghebreyesus told reporters that the U.N. organization was looking into it along with Indian regulators and the drugmaker from the reported Pharmaceuticals that four cough and cold syrups made by Maiden Pharmaceuticals in India may have been in link to the deaths of 66 children in the Gambia..

The death of 66 children in the Gambia, a country in West Africa, has stunned the world. The World Health Organization has issued a warning that the cough medicine manufactured by an Indian company is responsible for the deaths of children. The four products are Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup, according to the medical product alert released by WHO on Wednesday.

A detailed investigation was launched to ascertain the facts and details of the matter in collaboration with Haryana State Drugs Controller, the source explained. "The company has manufactured and exported these products only to The Gambia so far," the source said.

"At the same time, the exact one-to-one causal relation of death has not yet been provided by WHO, nor have the details of labels/ products been shared by WHO with CDSCO enabling it to confirm the identity/ source of the manufacturing of the products," it added.

Medical authorities in The Gambia, discovered an increase in cases of acute kidney injury among children under the age of five in late July, prompting the WHO's intervention. According to the World Health Organization's official website, "Laboratory analysis of samples of each of the four products confirms that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants. To date, these four products have been identified in The Gambia, but may have been distributed, through informal markets, to other countries or regions."

The statement further added a piece of warning advice, "WHO requests increased surveillance and diligence within the supply chains of countries and regions likely to be affected by these products. Increased surveillance of the informal/unregulated market is also advised,

If you have these substandard products, please DO NOT use them. If you, or someone you know, have used these products or suffered any adverse reaction/event after use, you are advised to seek immediate medical advice from a qualified healthcare professional and report the incident to the National Regulatory Authority or National Pharmacovigilance Centre," it added.